Jeffrey H Gertsch

Summary

Publications

  1. ncbi request reprint Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial
    Buddha Basnyat
    Nepal International Clinic, Himalayan Rescue Association
    High Alt Med Biol 4:45-52. 2003
  2. pmc Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)
    Jeffrey H Gertsch
    Department of Internal Medicine, Maricopa Medical Center, 2601 E Roosevelt Avenue number O D 10, Phoenix, AZ 85008, USA
    BMJ 328:797. 2004
  3. ncbi request reprint Neurological conditions at altitude that fall outside the usual definition of altitude sickness
    Buddha Basnyat
    Nepal International Clinic and Himalayan Rescue Association, Department of Physiology, Institute of Medicine and Patan Hospital, Kathmandi, NEPA
    High Alt Med Biol 5:171-9. 2004
  4. ncbi request reprint Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent
    Jeffrey H Gertsch
    The University of Hawaii, John A Burns School of Medicine, and the Kapiolani Clinical Research Center, Honolulu, Hawaii 96813, USA
    High Alt Med Biol 3:29-37. 2002
  5. ncbi request reprint Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial
    Buddha Basnyat
    Himalayan Rescue Association and Nepal International Clinic, Kathmandu, Nepal
    High Alt Med Biol 7:17-27. 2006

Detail Information

Publications5

  1. ncbi request reprint Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial
    Buddha Basnyat
    Nepal International Clinic, Himalayan Rescue Association
    High Alt Med Biol 4:45-52. 2003
    ..We concluded that acetazolamide 125 mg twice daily was effective in decreasing the incidence of AMS in this Himalayan trekking population...
  2. pmc Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)
    Jeffrey H Gertsch
    Department of Internal Medicine, Maricopa Medical Center, 2601 E Roosevelt Avenue number O D 10, Phoenix, AZ 85008, USA
    BMJ 328:797. 2004
    ..To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness...
  3. ncbi request reprint Neurological conditions at altitude that fall outside the usual definition of altitude sickness
    Buddha Basnyat
    Nepal International Clinic and Himalayan Rescue Association, Department of Physiology, Institute of Medicine and Patan Hospital, Kathmandi, NEPA
    High Alt Med Biol 5:171-9. 2004
    ....
  4. ncbi request reprint Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent
    Jeffrey H Gertsch
    The University of Hawaii, John A Burns School of Medicine, and the Kapiolani Clinical Research Center, Honolulu, Hawaii 96813, USA
    High Alt Med Biol 3:29-37. 2002
    ..Twenty-one of 26 (81%) subjects developed AMS overall. This is the first study to demonstrate that 1 day of pretreatment with ginkgo 60 mg TID may significantly reduce the severity of AMS prior to rapid ascent from sea level to 4205 m...
  5. ncbi request reprint Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial
    Buddha Basnyat
    Himalayan Rescue Association and Nepal International Clinic, Kathmandu, Nepal
    High Alt Med Biol 7:17-27. 2006
    ..02). We conclude that 125 mg bd of acetazolamide is not significantly different from 375 mg bd in the prevention of AMS; 125 mg bd should be considered the preferred dosage when indicated for persons ascending to altitudes above 2500 m...